For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Calithera Biosciences, Inc.

Calculating rank

USPTO Granted Patents = 30

% Expired Patents = 40.0

CIPO Patents = 2

EPO Patents = 12

Trademarks = 3

Forward Citations = 111

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

Jim W Li (14 out of 38 patents)

Lijing Chen (12 out of 16 patents)

Eric Brian Sjogren (11 out of 64 patents)

4. Timothy Friend Stanton (9 out of 11 patents)

5. Roland Joseph Billedeau (8 out of 23 patents)

6. Michael C Van Zandt (8 out of 44 patents)

7. Matthew I Gross (7 out of 7 patents)

8. Francesco Parlati (6 out of 21 patents)

9. Darren Whitehouse (5 out of 18 patents)

10. Susanne M Steggerda (4 out of 5 patents)

11. Guy Laidig (4 out of 4 patents)

12. Bindu Goyal (4 out of 10 patents)

13. Jennifer L Savoy (3 out of 3 patents)

14. Lene Raunkjær Petersen (3 out of 3 patents)

15. Susan D Bromley (3 out of 3 patents)

Core Competencies:

Arginase Inhibitors

Glutaminase Inhibitors

Combination Therapy

Ectonucleotidase Inhibitors

Heterocyclic Compounds

Cancer Treatment

Immuno-Oncology

Solid State Forms

30 patents: Sort by Forward Citations

1. 11370754 - Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide (2022-06-28),

2. 11352355 - Solid state forms of fused heteroaromatic pyrrolidinones (2022-06-07),

3. 11291674 - Arginase inhibitor combination therapies (2022-04-05),

4. 11208414 - Ectonucleotidase inhibitors and methods of use thereof (2021-12-28),

5. 11078228 - Ectonucleotidase inhibitors and methods of use thereof (2021-08-03),

6. 11034715 - Ectonucleotidase inhibitors and methods of use thereof (2021-06-15),

7. 11021495 - Compositions and methods for inhibiting arginase activity (2021-06-01),

8. 10940148 - Combination therapy with glutaminase inhibitors and immuno-oncology agents (2021-03-09),

9. 10906872 - Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide (2021-02-02),

10. 10905701 - Compositions and methods for inhibiting arginase activity (2021-02-02),

11. 10851118 - Compositions and methods for inhibiting arginase activity (2020-12-01),

12. 10844080 - Compositions and methods for inhibiting arginase activity (2020-11-24),

13. 10793535 - Heterocyclic glutaminase inhibitors (2020-10-06),

14. 10676472 - Crystal forms of glutaminase inhibitors (2020-06-09),

15. 10597411 - Compositions and methods for inhibiting arginase activity (2020-03-24),

Company Overview

Calithera Biosciences, Inc. is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for cancer and other serious diseases. The company specializes in small molecule drugs that target key metabolic pathways in tumors, aiming to improve patient outcomes through precision medicine. With a commitment to advancing scientific research, Calithera is dedicated to discovering and delivering transformative treatments that address unmet medical needs in oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

30 Patents

#46 in South San Francisco, CA

#2,686 in California

#11,286 in US

#21,907 in the World

South San Francisco, CA, United States of America

Calithera Biosciences, Inc.

Forward Citations = 111

45 inventors:

Jim W Li (14 out of 38 patents)

Lijing Chen (12 out of 16 patents)

Eric Brian Sjogren (11 out of 64 patents)

4. Timothy Friend Stanton (9 out of 11 patents)

5. Roland Joseph Billedeau (8 out of 23 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Calithera Biosciences, Inc.. Retrieved from https://idiyas.com/company/calithera-biosciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…